Menu
Search
|

Menu

Close
X

Omeros Corp OMER.OQ (NASDAQ Stock Exchange Global Market)

14.55 USD
-- (--)
As of Jul 22
Previous Close 14.55
Open --
Volume --
3m Avg Volume 134,040
Today’s High --
Today’s Low --
52 Week High 27.00
52 Week Low 10.30
Shares Outstanding (mil) 49.06
Market Capitalization (mil) 718.70
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.17 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY19
22
FY18
30
FY17
65
FY16
42
EPS (USD)
FY19
-0.497
FY18
-2.610
FY17
-1.177
FY16
-1.652
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.52
Price to Sales (TTM)
vs sector
14.36
7.97
Price to Book (MRQ)
vs sector
--
4.45
Price to Cash Flow (TTM)
vs sector
--
24.33
Total Debt to Equity (MRQ)
vs sector
--
17.60
LT Debt to Equity (MRQ)
vs sector
--
12.58
Return on Investment (TTM)
vs sector
-199.84
12.69
Return on Equity (TTM)
vs sector
--
17.17

EXECUTIVE LEADERSHIP

Gregory Demopulos
Chairman of the Board, President, Chief Executive Officer, Since 2013
Salary: $770,483.00
Bonus: $700,000.00
Michael Jacobsen
Chief Accounting Officer, Vice President - Finance, Treasurer, Since 2013
Salary: $352,814.00
Bonus: $69,010.00
George Gaitanaris
Chief Scientific Officer, Vice President - Science, Since 2012
Salary: --
Bonus: --
Peter Cancelmo
Vice President, General Counsel, Corporate Secretary, Since 2019
Salary: --
Bonus: --
Christopher Bral
Vice President - Nonclinical Development, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

201 Elliott Ave W
SEATTLE   WA   98119-4240

Phone: +1206.6765000

Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens (IOL) replacement. The Company’s clinical-stage development programs are focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington’s disease and cognitive impairment, and addictive and compulsive disorders. It also offers a diverse group of preclinical programs and platforms that are used to unlock new G protein-coupled receptor (GPCR) drug targets and to generate antibodies.

SPONSORED STORIES